GlassScriptPhysician profile
Alfonso A Haro
NPI 1013902865
$1,273.01
in general payments reported to CMS, 2019-2025
23 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $14.40 · 2021: $46.81 · 2022: $387 · 2023: $212 · 2024: $222 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $611.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $611.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $342.46 | 2022-2023 | Senza |
| Medtronic, INC. | $101.57 | 2022-2025 | Inceptiv, Intellis Adaptivestim, Accurian |
| Averitas Pharma INC. | $82.33 | 2023-2024 | Qutenza |
| Triad Life Sciences INC. | $79.90 | 2022 | |
| Smith+Nephew, INC. | $72.89 | 2019-2024 | Grafix Pl, Oasis, Stravix |
| Melinta Therapeutics, LLC | $60.36 | 2019 | |
| Organogenesis INC. | $56.57 | 2021-2025 | Apligraf |
| Bioventus LLC | $53.58 | 2022-2025 | Exogen Ultrasound Bone Healing System |
| Kerecis Limited | $46.64 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Ani Pharmaceuticals, INC. | $46.35 | 2025 | Purified Cortrophin Gel |
| Tricoast Surgical Solutions LLC | $43.67 | 2024 | |
| Treace Medical Concepts, INC. | $35.68 | 2024-2025 | |
| Globus Medical, INC. | $31.66 | 2025 | Senza |
| Grt US Holding, INC. | $30.54 | 2022 | |
| Rikco International, LLC | $27.39 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $24.24 | 2023 | Hymovis, Triluron |
| Arthrosurface Incorporated | $23.98 | 2019 | |
| Abbott Laboratories | $23.28 | 2021 | |
| Zimvie INC. | $22.86 | 2022 | |
| Polarityte, INC. | $22.43 | 2019 | |
| Medartis INC. | $18.51 | 2019 | |
| Merck Sharp & Dohme LLC | $13.37 | 2019 | |
| Zimmer Biomet Holdings, INC. | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfonso Haro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.